MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2017 International Congress

    Interval from onset of Parkinson disease to onset of motor and non-motor complications in Leucine-rich repeat kinase 2 (LRRK2) G2019S positive versus matched PD controls

    S. Gunzler, D. Riley, A. Wilson-Delfosse, S. Chen, J. Mieyal, C. Tatsuoka (Cleveland, OH, USA)

    Objective: To compare the latency between onset of Parkinson disease (PD) symptoms and onset of motor and non-motor complications of PD, between G2019S LRRK2 mutation…
  • 2017 International Congress

    Spiral Analysis is a Promising Biomarker in LRRK2 G2019S carriers

    R. Ortega, M. Pullman, A. Glickman, I. Perera, M. San Luciano, A. Mirelman, C. Pont-Sunyer, N. Giladi, E. Tolosa, Q. Yu, S. Bressman, S. Pullman, R. Saunders-Pullman (New York, NY, USA)

    Objective: To assess whether harboring a LRRK2 G2019S mutation is associated with abnormalities in spiral drawing, including in mutation carriers with Parkinson Disease (PD) as…
  • 2017 International Congress

    Screening of GBA and LRRK2 G2019S Mutations in Egyptian Parkinson’s Disease Patients

    L. R'Bibo, S. Hamed, H. Houlden, N. Wood (London, United Kingdom)

    Objective: We aim to estimate the frequency of mutations in the glucocerebrosidase gene (GBA) and LRRK2 G2019S in a yet unstudied Egyptian Parkinson's disease population from the…
  • 2017 International Congress

    Neuromelanin Magnetic Resonance Imaging of the Substatia Nigra in LRRK2 -related Parkinson’s disease

    L. Correia Guedes, S. Reimão, P. Paulino, R. Nunes, R. Bouça, D. Abreu, N. Gonçalves, T. Soares, M. Fabbri, C. Godinho, P. Lobo, D. Neutel, M. Quadri, M. Coelho, M.M. Rosa, J. Campos, T. Outeiro, C. Sampaio, V. Bonifati, J. Ferreira (Lisbon, Portugal)

    Objective: Our study aimed to evaluate neuromelanin-Magnetic Resonance signal changes in PD patients carrying a LRRK2 mutation. Background: Specific magnetic resonance (MR) sequences are able to…
  • 2016 International Congress

    High throughput pooled-DNA sequencing of mendelian/susceptibility Parkinson’s disease genes in Spanish population

    S. Ortega-Cubero, O. Lorenzo-Betancor, E. Lorenzo, B.A. Benitez, C. Cruchaga, L. Samaranch, M. Diez, J.A. Obeso, M.C. Rodriguez-Oroz, M. Aguilar, M.A. Pastor, P. Pastor (Palencia, Spain)

    Objective: The primary outcome of our study was the identification of rare variants in 5 major Mendelian PD genes (SNCA, PARK2, PINK1, DJ1, LRRK2) and…
  • 2016 International Congress

    A novel haplotype in LRRK2 is associated with risk for multiple system atrophy in the Korean population

    L.L. Farrell, E. Scott, H.J. Kim, I. Guella, S. Bortnick, E.M. Nosova, B. Jeon, C.W. Sin, H. Park, S.S. Park, M.J. Farrer (Vancouver, Cameroon)

    Objective: To (1) validate past results by investigating the role of LRRK2 exonic variants in an equivalent Korean series with MSA and (2) identify novel…
  • 2016 International Congress

    Defective ubiquitinated mitochondria accumulation in aged Parkinsonian LRRK2R1441G knockin mice

    H.F. Liu, P.W.L. Ho, L.F. Li, G.C.T. Leung, C.S.C. Lam, M.H.W. Kung, D.B. Ramsden, S.L. Ho (Hong Kong, Hong Kong)

    Objective: (1) To determine potential accumulation of defective ubiquitinated mitochondria in the brains of aged LRRK2R1441G knockin (KI) mice and their age-matched wildtype controls; and…
  • 2016 International Congress

    Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease

    J. Varghese, K. Terpstra, S. Chiu, R. Mishra, Y. Bureau (London, ON, Canada)

    Objective: The objective of our study was to characterize the behavioral phenotype of the transgenic LRRK-2 rat in the context of PD model and to…
  • 2016 International Congress

    Detection of leucine-rich repeat kinase 2 in human biofluids

    E. Mutez, W. Sibran, T. Comptdaer, P. Semaille, M. Drouyer, S. Bleuse, L. Defebvre, A. Destee, M.C. Chartier-Harlin, J.M. Taymans (Lille, France)

    Objective: To evaluate the presence of leucine-rich repeat kinase 2 (LRRK2) in human biosamples, including cerebrospinal fluid (CSF) and urine, as a first step towards…
  • 2016 International Congress

    A cognitive fMRI study of non-manifesting LRRK2 and GBA carriers

    A. Thaler, N. Bregman, A. Mirelman, T. Gurevich, M. Gana-Weiss, A. Orr-Urtreger, T. Hendler, N. Giladi (Tel-Aviv, Israel)

    Objective: To assess the cognitive profile of non-manifesting carriers of GBA and LRRK2 mutations using two fMRI tasks: a Stroop interference and N-Back working memory…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley